Clinical Trial Update: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) [Phase 3]

View source ↗

Summary

A Phase 3 study of Sacituzumab Tirumotecan (MK-2870) as a single agent and in combination with pembrolizumab (MK-3475) versus physician's choice in HR+/HER2- un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Sacituzumab Tirumotecan (MK-2870) (sacituzumab tirumotecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Neoplasms | Phase 3 | Status: RECRUITING